US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
DE3303707A1
(de)
|
1983-02-04 |
1984-08-09 |
Dynamit Nobel Ag, 5210 Troisdorf |
Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
JPH01167840A
(ja)
|
1987-12-24 |
1989-07-03 |
Konica Corp |
新規な写真用シアンカプラー
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
DE69222847T3
(de)
|
1991-04-16 |
2005-09-15 |
Nippon Shinyaku Co., Ltd. |
Verfahren zur herstellung einer festen dispersion
|
KR100274734B1
(ko)
|
1991-11-22 |
2000-12-15 |
제이코버스 코넬리스 레이서 |
리제드로네이트 지연-방출성 조성물
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
WO1994008568A1
(en)
|
1992-10-16 |
1994-04-28 |
Nippon Shinyaku Co., Ltd. |
Method of manufacturing wax matrices
|
GB9226855D0
(en)
|
1992-12-23 |
1993-02-17 |
Erba Carlo Spa |
Vinylene-azaindole derivatives and process for their preparation
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US6326469B1
(en)
|
1994-04-22 |
2001-12-04 |
Sugen, Inc. |
Megakaryocytic protein tyrosine kinases
|
CA2220451A1
(en)
|
1995-05-17 |
1996-11-21 |
Cedars-Sinai Medical Center |
Methods and compositions for improving digestion and absorption in the small intestine
|
US5593997A
(en)
|
1995-05-23 |
1997-01-14 |
Pfizer Inc. |
4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
|
US5994348A
(en)
|
1995-06-07 |
1999-11-30 |
Sanofi |
Pharmaceutical compositions containing irbesartan
|
CH690773A5
(de)
|
1996-02-01 |
2001-01-15 |
Novartis Ag |
Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
|
AU3176297A
(en)
|
1996-06-25 |
1998-01-14 |
Novartis Ag |
Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
|
AU748884B2
(en)
|
1997-03-19 |
2002-06-13 |
Abbott Gmbh & Co. Kg |
Pyrrolo(2,3d)pyrimidines and their use as tyrosine kinase inhibitors
|
DK0901786T3
(da)
|
1997-08-11 |
2007-10-08 |
Pfizer Prod Inc |
Faste farmaceutiske dispersioner med foröget biotilgængelighed
|
DE69808670T2
(de)
|
1997-12-31 |
2003-07-03 |
Choongwae Pharma Corp |
Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
DE69918089T2
(de)
|
1998-04-17 |
2005-07-14 |
Parker Hughes Institute, St. Paul |
Btk inhibitoren und verfahren zur identifizierung und verwendung
|
US7122207B2
(en)
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
US6998233B2
(en)
|
1998-06-26 |
2006-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
US20050287596A9
(en)
|
1998-06-26 |
2005-12-29 |
Braisted Andrew C |
Novel ligands and libraries of ligands
|
UA74141C2
(uk)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
ES2307482T3
(es)
|
1999-02-10 |
2008-12-01 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas.
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
CZ2002936A3
(cs)
|
1999-09-17 |
2002-10-16 |
Abbott Gmbh & Co. Kg |
Pyrazolopyrimidiny jako terapeutické prostředky
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
WO2001025238A2
(en)
|
1999-10-06 |
2001-04-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
WO2001041754A2
(en)
|
1999-11-30 |
2001-06-14 |
Parker Hughes Institute |
Inhibitors of collagen-induced platelet aggregation
|
JP2003532632A
(ja)
|
1999-12-17 |
2003-11-05 |
アライアッド・ファーマシューティカルズ・インコーポレーテッド |
新規の複素環
|
GB0005345D0
(en)
|
2000-03-06 |
2000-04-26 |
Mathilda & Terence Kennedy Ins |
Methods of treating sepsis septic shock and inflammation
|
GB0108903D0
(en)
|
2000-10-05 |
2001-05-30 |
Aventis Pharm Prod Inc |
Novel crystalline forms of a factor Xa inhibitor
|
JP2004533209A
(ja)
|
2000-10-23 |
2004-11-04 |
ブリストル−マイヤーズ スクイブ カンパニー |
ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
|
AU2002232492A1
(en)
|
2000-12-06 |
2002-06-18 |
Pharmacia Corporation |
Rapidly dispersing pharmaceutical composition comprising effervescent agents
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US8306897B2
(en)
|
2001-05-04 |
2012-11-06 |
Stockshield, Inc. |
Method and system for insuring against investment loss
|
WO2003000187A2
(en)
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
|
US20030119060A1
(en)
|
2001-08-10 |
2003-06-26 |
Desrosiers Peter J. |
Apparatuses and methods for creating and testing pre-formulations and systems for same
|
CA2810339A1
(en)
|
2001-08-10 |
2003-02-20 |
Novartis Ag |
Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
|
WO2003016338A1
(en)
|
2001-08-15 |
2003-02-27 |
Parker Hughes Institute |
Crystal structure of the btk kinase domain
|
IL161409A0
(en)
|
2001-11-21 |
2004-09-27 |
Sunesis Pharmaceuticals Inc |
Methods for ligand discovery
|
US20050084905A1
(en)
|
2002-03-21 |
2005-04-21 |
Prescott John C. |
Identification of kinase inhibitors
|
GB2388594A
(en)
|
2002-05-16 |
2003-11-19 |
Bayer Ag |
Imidazo-triazine PDE 4 inhibitors
|
EP1529046A1
(en)
|
2002-08-08 |
2005-05-11 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Substituted benzimidazole compounds
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO2005000197A2
(en)
|
2003-04-11 |
2005-01-06 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
US20050008640A1
(en)
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
EP1473039A1
(en)
|
2003-05-02 |
2004-11-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
US7393848B2
(en)
|
2003-06-30 |
2008-07-01 |
Cgi Pharmaceuticals, Inc. |
Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
|
US8131475B2
(en)
|
2003-09-03 |
2012-03-06 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
EP1664762A4
(en)
|
2003-09-03 |
2008-08-13 |
Us Gov Health & Human Serv |
METHODS OF IDENTIFICATION, DIAGNOSIS AND PREDICTION FOR LYMPHOMES SURVIVAL
|
CN1897950A
(zh)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
稠合芳基和杂芳基衍生物及其使用方法
|
SG132683A1
(en)
|
2003-10-15 |
2007-06-28 |
Osi Pharm Inc |
Imidazopyrazine tyrosine kinase inhibitors
|
WO2005060956A1
(en)
|
2003-12-12 |
2005-07-07 |
University Of Maryland, Baltimore |
IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
|
US20050153990A1
(en)
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
US20070281907A1
(en)
|
2003-12-22 |
2007-12-06 |
Watkins William J |
Kinase Inhibitor Phosphonate Conjugates
|
ATE383859T1
(de)
|
2004-01-08 |
2008-02-15 |
Wyeth Corp |
Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
|
JP2007519742A
(ja)
|
2004-01-26 |
2007-07-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼの阻害剤として有用な組成物
|
WO2005074603A2
(en)
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
ITMI20041314A1
(it)
|
2004-06-30 |
2004-09-30 |
Nuvera Fuel Cells Europ Srl |
Dispositivo di raffreddamento per celle a combustibili a membrana
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
US20060079494A1
(en)
|
2004-09-27 |
2006-04-13 |
Santi Daniel V |
Specific kinase inhibitors
|
KR20070063562A
(ko)
|
2004-09-28 |
2007-06-19 |
얀센 파마슈티카 엔.브이. |
치환 디피페리딘 ccr2 길항제
|
JP2008519843A
(ja)
|
2004-11-10 |
2008-06-12 |
シージーアイ ファーマスーティカル インコーポレーテッド |
特定のイミダゾ[1,2−a]ビラジン−8−イラミンズ、その生成方法及びそれに関する使用方法
|
GB0425035D0
(en)
|
2004-11-12 |
2004-12-15 |
Novartis Ag |
Organic compounds
|
BRPI0608840B8
(pt)
|
2005-03-07 |
2021-05-25 |
Batyer Healthcare Ag |
composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
|
KR101357524B1
(ko)
|
2005-03-10 |
2014-02-03 |
질레드 코네티컷 인코포레이티드 |
특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
|
KR20080025039A
(ko)
|
2005-05-13 |
2008-03-19 |
아이알엠 엘엘씨 |
단백질 키나제 억제제로서의 화합물 및 조성물
|
MX2007014782A
(es)
|
2005-05-23 |
2008-02-19 |
Novartis Ag |
Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
|
PE20070100A1
(es)
|
2005-06-22 |
2007-03-10 |
Plexxikon Inc |
DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO MODULADORES DE QUINASAS
|
US20070065449A1
(en)
|
2005-09-16 |
2007-03-22 |
Claire Verschraegen |
Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
|
CA2629314A1
(en)
|
2005-11-12 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Tec kinase inhibitors
|
JP2009523724A
(ja)
|
2006-01-13 |
2009-06-25 |
ファーマサイクリクス,インコーポレイテッド |
チロシンキナーゼ阻害剤およびその使用方法
|
JP2009525468A
(ja)
|
2006-01-30 |
2009-07-09 |
ザ・スクリプス・リサーチ・インステイチユート |
循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法
|
AU2007226983A1
(en)
|
2006-03-20 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
KR20090017498A
(ko)
|
2006-04-04 |
2009-02-18 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
Pi3 키나제 길항물질
|
EP2027087A2
(en)
|
2006-05-18 |
2009-02-25 |
MannKind Corporation |
Intracellular kinase inhibitors
|
DE102006026583A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
|
SI2530083T1
(sl)
|
2006-09-22 |
2016-09-30 |
Pharmacyclics Llc |
Inhibitorji Bruton tirozin kinaze
|
ES2403546T3
(es)
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
FI20080352A0
(fi)
|
2008-05-09 |
2008-05-09 |
Atacama Labs Oy |
Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
|
RU2009131749A
(ru)
|
2007-01-22 |
2011-02-27 |
Новавакс, Инк. (Us) |
Многофазные фармацевтические композиции плохо растворимых в воде лекарственных соединений для уменьшения вариабельности при приеме после еды/натощак и для улучшения пероральной биодоступности
|
NL2000640C2
(nl)
|
2007-03-05 |
2008-09-08 |
Stichting Wetsus Ct Of Excelle |
Werkwijze en systeem voor het zuiveren van een vloeistof.
|
ES2562215T3
(es)
|
2007-03-28 |
2016-03-03 |
Pharmacyclics Llc |
Inhibidores de la tirosina quinasa de Bruton
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US20090010911A1
(en)
|
2007-04-06 |
2009-01-08 |
Iowa State University Research Foundation, Inc. |
Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
|
ES2453947T3
(es)
|
2007-04-27 |
2014-04-09 |
Purdue Pharma Lp |
Antagonistas de TRPV1 y usos de los mismos
|
MX2010001244A
(es)
|
2007-07-30 |
2010-08-31 |
Ardea Biosciences Inc |
Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek asi como composiciones, metodos de uso y de preparacion de los mismos.
|
TWI552752B
(zh)
|
2007-10-19 |
2016-10-11 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
EP2426109B1
(en)
|
2007-10-23 |
2013-12-18 |
F. Hoffmann-La Roche AG |
Novel kinase inhibitors
|
US8426441B2
(en)
|
2007-12-14 |
2013-04-23 |
Roche Palo Alto Llc |
Inhibitors of bruton's tyrosine kinase
|
US20150152115A1
(en)
|
2007-12-27 |
2015-06-04 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
EP3090743A1
(en)
|
2008-01-09 |
2016-11-09 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions for treating headache and eliminating nausea
|
CA2720744A1
(en)
|
2008-04-09 |
2009-10-15 |
Lek Pharmaceuticals D.D. |
Granulation of active pharmaceutical ingredients
|
KR20110014149A
(ko)
|
2008-04-14 |
2011-02-10 |
아디아 바이오사이언스즈 인크. |
조성물 및 이것의 제조 및 사용 방법
|
EP2123626A1
(en)
|
2008-05-21 |
2009-11-25 |
Laboratorios del Dr. Esteve S.A. |
Co-crystals of duloxetine and co-crystal formers for the treatment of pain
|
JP2011526299A
(ja)
|
2008-06-27 |
2011-10-06 |
アビラ セラピューティクス, インコーポレイテッド |
ヘテロアリール化合物およびそれらの使用
|
AU2009270856B2
(en)
|
2008-07-16 |
2013-07-25 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
|
ES2620442T3
(es)
|
2008-07-29 |
2017-06-28 |
Frontier Scientific, Inc. |
Uso de derivados de tetraquis(N-alquilpiridinio)-porfirina para la destrucción de microbios o la prevención de su crecimiento
|
US8314122B2
(en)
*
|
2008-10-09 |
2012-11-20 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Using of organic solvents in wet granulation of moxifloxacin
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
WO2010126960A1
(en)
|
2009-04-29 |
2010-11-04 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
NZ603643A
(en)
|
2010-05-31 |
2014-07-25 |
Ono Pharmaceutical Co |
Purinone derivative
|
EP2575818A4
(en)
|
2010-06-03 |
2013-11-06 |
Pharmacyclics Inc |
USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
LT2975042T
(lt)
|
2010-06-23 |
2019-01-25 |
Hanmi Science Co., Ltd. |
Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui
|
EP2603081B1
(en)
|
2010-08-10 |
2016-10-05 |
Celgene Avilomics Research, Inc. |
Besylate salt of a btk inhibitor
|
UA110347C2
(uk)
|
2010-08-12 |
2015-12-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
|
US8541391B2
(en)
|
2010-10-28 |
2013-09-24 |
Viropharma Incorporated |
Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
|
US8501484B2
(en)
|
2011-03-14 |
2013-08-06 |
Los Alamos National Security, Llc |
Preparation of cerium halide solvate complexes
|
MX2011004759A
(es)
|
2011-05-04 |
2012-11-21 |
Senosiain S A De C V Lab |
Nuevas formas solidas de antibioticos.
|
EP2710005B1
(en)
|
2011-05-17 |
2016-10-05 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
EP2734207A4
(en)
*
|
2011-07-18 |
2015-06-17 |
Tokai Pharmaceuticals Inc |
NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
|
KR101982475B1
(ko)
|
2011-09-02 |
2019-05-27 |
인사이트 홀딩스 코포레이션 |
Pi3k 억제제로서 헤테로시클릴아민
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
EP3181128B1
(en)
|
2012-01-13 |
2023-03-08 |
XSpray Pharma AB (publ) |
Nilotinib pharmaceuticalcomposition
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
JP5514256B2
(ja)
|
2012-05-18 |
2014-06-04 |
株式会社東芝 |
磁気記憶素子及びその製造方法
|
KR20220093389A
(ko)
*
|
2012-06-04 |
2022-07-05 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
EP2861599B1
(en)
|
2012-06-18 |
2019-12-18 |
Principia Biopharma Inc. |
Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment of cancer and autoimmune diseases
|
US20150140085A1
(en)
*
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
JP6575950B2
(ja)
|
2012-07-24 |
2019-09-18 |
ファーマサイクリックス エルエルシー |
Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異
|
CN103121999A
(zh)
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
一种酪氨酸激酶抑制剂pci-32765的合成方法
|
PE20151495A1
(es)
|
2012-11-15 |
2015-10-23 |
Pharmacyclics Inc |
Compuestos de pirrolopirimidina como inhibidores de quinasas
|
MX369503B
(es)
|
2013-04-08 |
2019-11-11 |
Pharmacyclics Llc |
Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
|
WO2014179528A2
(en)
|
2013-05-01 |
2014-11-06 |
Brown Dennis M |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
|
AU2014273946B2
(en)
|
2013-05-30 |
2020-03-12 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
JP6800750B2
(ja)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
固形腫瘍の処置方法
|
WO2015034478A1
(en)
|
2013-09-04 |
2015-03-12 |
Halliburton Energy Services, Inc. |
Scale-inhibiting cocrystals for treatment of a subterranean formation
|
US10526660B2
(en)
|
2013-09-12 |
2020-01-07 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
CN104447701B
(zh)
|
2013-09-17 |
2019-03-22 |
广东东阳光药业有限公司 |
吡唑类衍生物及其用途
|
TWI617309B
(zh)
|
2013-10-25 |
2018-03-11 |
製藥公司 |
使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
|
WO2015071432A1
(en)
|
2013-11-14 |
2015-05-21 |
Sandoz Ag |
Pharmaceutical compositions of ibrutinib
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
CA2933900A1
(en)
|
2013-12-20 |
2015-06-25 |
Georgia Tech Research Corporation |
Formulations and methods for targeted ocular delivery of therapeutic agents
|
CN106008515A
(zh)
|
2014-01-29 |
2016-10-12 |
苏州晶云药物科技有限公司 |
依鲁替尼的新晶型及其制备方法
|
US10166183B2
(en)
|
2014-02-07 |
2019-01-01 |
Auspex Pharmaceuticals, Inc. |
Pharmaceutical formulations
|
WO2015123654A1
(en)
|
2014-02-17 |
2015-08-20 |
The Cleveland Clinic Foundation |
Amine passivated nanoparticles for cancer treatment and imaging
|
US20150238490A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
US20150267752A1
(en)
|
2014-03-19 |
2015-09-24 |
Roller Bearing Company Of America, Inc. |
Bearing outer race having a radially inwardly biased seal
|
WO2015143400A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics, Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
US9884869B2
(en)
|
2014-03-27 |
2018-02-06 |
Perrigo Api Ltd. |
Ibrutinib solid forms and production process therefor
|
CN105085529A
(zh)
|
2014-05-15 |
2015-11-25 |
广东东阳光药业有限公司 |
依鲁替尼新晶型及其制备方法
|
US9127069B1
(en)
*
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
WO2016020697A1
(en)
|
2014-08-06 |
2016-02-11 |
Cipla Limited |
Pharmaceutical compositions of polymeric nanoparticles
|
KR20170033358A
(ko)
|
2014-08-07 |
2017-03-24 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나아제 저해제의 신규한 제제
|
WO2016025720A1
(en)
|
2014-08-14 |
2016-02-18 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
EP3201197B1
(en)
|
2014-10-01 |
2019-03-27 |
ratiopharm GmbH |
Acid addition salt of ibrutinib
|
CN104523695A
(zh)
|
2014-11-12 |
2015-04-22 |
广东东阳光药业有限公司 |
一种治疗过度增生性疾病的药物组合物
|
CN105640961A
(zh)
|
2014-11-18 |
2016-06-08 |
山东瑞禾医药科技有限公司 |
一种含依鲁替尼的药物组合物
|
WO2016079216A1
(en)
|
2014-11-20 |
2016-05-26 |
Sandoz Ag |
Physical forms of ibrutinib, a bruton's kinase inhibitor
|
US20150224060A1
(en)
|
2015-01-03 |
2015-08-13 |
David Wong |
Gastric retentive tablet compositions
|
CZ201584A3
(cs)
|
2015-02-09 |
2016-08-17 |
Zentiva, K.S. |
Sůl Ibrutinib sulfátu
|
DK3265084T3
(da)
*
|
2015-03-03 |
2024-02-12 |
Pharmacyclics Llc |
Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
|
JP2018511580A
(ja)
|
2015-03-03 |
2018-04-26 |
ドクター レディズ ラボラトリーズ リミテッド |
イブルチニブの多形体
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
ES2733460T3
(es)
|
2015-04-02 |
2019-11-29 |
Ratiopharm Gmbh |
Co-cristales de Ibrutinib
|
UA125681C2
(uk)
|
2015-04-06 |
2022-05-18 |
Янссен Фармацевтика Нв |
Композиції, які містять ібрутиніб
|
CN105294696A
(zh)
|
2015-11-19 |
2016-02-03 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
CN105440040B
(zh)
|
2015-12-23 |
2018-03-13 |
浙江京新药业股份有限公司 |
依鲁替尼的纯化方法
|
WO2017125423A1
(en)
*
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a btk inhibitor
|
EP3405178A1
(en)
*
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica NV |
Formulations/compositions comprising a btk inhibitor
|
CN105646484A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
晶型b及制备方法
|
CN105646498A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型f及制备方法
|
CN105646499A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型g及制备方法
|
CN106619643A
(zh)
|
2016-11-11 |
2017-05-10 |
上海雅本化学有限公司 |
一种含依鲁替尼的药物组合物
|